Sumitomo Pharma
Japanese multinational pharmaceutical company focused on psychiatry, neurology, oncology, women's health, urology, rare diseases, and related therapeutic areas.
Last updated August 31, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Sumitomo Pharma is a Japanese multinational pharmaceutical company headquartered in Osaka. The company develops and commercializes prescription medicines in areas including psychiatry, neurology, oncology, women's health, urology, rare diseases, and cell and gene therapies. Its present identity emerged from the 2005 merger of Dainippon Pharmaceutical and Sumitomo Pharmaceuticals, followed by a corporate name change from Sumitomo Dainippon Pharma to Sumitomo Pharma in April 2022. The company's historical roots reach back to 1885, when Nagayo Sensai established Dainippon Pharmaceuticals with technical support from Shibata Shokei and Nagai Nagayoshi. The original operation used equipment imported from Germany and manufactured tinctures and other medicines listed in the Japanese Pharmacopoeia. One of its early products was ephedrine, an anti-asthma medicine associated with Nagai. After Nagai's departure in 1893, the business experienced operating losses and was acquired by Osaka Seiyaku in 1898. The historical record also includes the production of methamphetamine under the Philopon brand for the Imperial Japanese military during the Second World War. Sumitomo Pharmaceuticals was incorporated separately in 1984 as a subsidiary of Sumitomo Chemical. The 2005 merger with Dainippon created Dainippon Sumitomo Pharma, later known as Sumitomo Dainippon Pharma. Sumitomo Chemical retained majority ownership after the transaction, providing the company with a continuing connection to the wider Sumitomo corporate group. A major strategic turning point came in 2009, when the company acquired United States-based Sepracor, a NASDAQ-traded pharmaceutical business, for approximately US$2.6 billion. The acquired business was renamed Sunovion in 2010 and supplied a North American commercial platform that the parent company had previously lacked. Through Sunovion, the group marketed Latuda, an atypical antipsychotic approved for schizophrenia and depressive episodes associated with bipolar I disorder. Other products associated with the Sunovion portfolio included Lunesta, Aptiom, and Brovana. The company expanded its central-nervous-system portfolio through Sunovion's approximately US$624 million acquisition of Cynapsus Therapeutics in 2016. The transaction brought Kynmobi, a sublingual apomorphine product candidate for Parkinson's disease, into the group. In 2019, Sumitomo Dainippon Pharma announced an approximately US$3 billion upfront transaction to acquire five Roivant subsidiaries, including Urovant and Enzyvant. This move broadened the company's exposure to urology, rare diseases, and other specialty pharmaceutical opportunities. In 2022, the company adopted the Sumitomo Pharma name. It subsequently announced an agreement in October 2022 to acquire all outstanding shares of Myovant, a former Roivant subsidiary in which it had previously been a majority owner. The transaction was valued at approximately US$2.9 billion and was completed in April 2023. Afterward, the company consolidated its United States subsidiaries into Sumitomo Pharma America, Inc., a wholly owned biopharmaceutical subsidiary focused on areas described by the company as critical patient needs, including psychiatry and neurology, oncology, urology, women's health, rare disease, and cell and gene therapies. Sumitomo Pharma therefore combines a long-established Japanese pharmaceutical heritage with a multinational specialty-drug strategy. Its business has been shaped by mergers, acquisitions, international commercialization, and a concentration on complex or high-need therapeutic categories rather than consumer healthcare.
History
Sumitomo Pharma's historical lineage begins with Dainippon Pharmaceuticals, established in 1885 by Nagayo Sensai, a graduate of Tekijuku, the private medical school founded by Ogata Kōan. The enterprise was privately funded by individuals from Tokyo and Osaka, while the government supplied land and buildings. Shibata Shokei and Nagai Nagayoshi provided technical expertise. Production began with equipment imported from Germany and focused on tinctures and other medicines recognized in the Japanese Pharmacopoeia. Ephedrine, associated with Nagai's work and used in asthma treatment, was among the early products. Nagai left the company in 1893, after which the business began recording operating losses. Osaka Seiyaku acquired it in 1898. During the Second World War, the historical Dainippon business produced methamphetamine under the Philopon brand for the Imperial Japanese military, a significant and controversial part of its prewar and wartime history. A separate corporate predecessor, Sumitomo Pharmaceuticals, was incorporated in 1984 as a subsidiary of Sumitomo Chemical. The two lineages were brought together on October 1, 2005, when Dainippon and Sumitomo Pharmaceuticals merged to form Dainippon Sumitomo Pharma. Sumitomo Chemical retained majority ownership after the merger, and the company later used the name Sumitomo Dainippon Pharma. International expansion became central to the company's development. In 2009, Sumitomo Dainippon Pharma acquired Sepracor, a NASDAQ-traded United States pharmaceutical company, for approximately US$2.6 billion. The acquired company was renamed Sunovion in 2010 and became the group's principal North American commercial platform. Sunovion supported the marketing of Latuda, an atypical antipsychotic approved for schizophrenia and bipolar I depression, as well as products including Lunesta, Aptiom, and Brovana. Sunovion continued to expand the group's central-nervous-system capabilities through its 2016 acquisition of Cynapsus Therapeutics for approximately US$624 million. Cynapsus brought Kynmobi, a sublingual apomorphine product candidate for Parkinson's disease. In September 2019, Sumitomo Dainippon Pharma announced an approximately US$3 billion upfront acquisition of five Roivant subsidiaries, among them Urovant and Enzyvant. The transaction extended the company's reach into urology, rare diseases, and other specialty areas. The company changed its name to Sumitomo Pharma on April 1, 2022. In October of the same year, it announced the acquisition of all outstanding Myovant shares at an announced valuation of approximately US$2.9 billion. Myovant had previously been a Roivant subsidiary and had already been majority-owned by Sumitomo Pharma. Following completion in April 2023, the company reorganized its United States businesses under Sumitomo Pharma America, Inc., a wholly owned biopharmaceutical subsidiary. The reorganized United States platform was described as serving critical patient needs across psychiatry and neurology, oncology, urology, women's health, rare disease, and cell and gene therapies. The company's evolution thus reflects a transition from a primarily Japanese pharmaceutical heritage toward a multinational specialty-pharmaceutical and biopharmaceutical model built through internal development, brand commercialization, and acquisitions.
- 2023
Sumitomo Pharma America is formed
[1]After the Myovant transaction, the company's United States subsidiaries are consolidated into Sumitomo Pharma America, Inc.
- 2022
The company adopts the Sumitomo Pharma name
[1]The corporate name changes from Sumitomo Dainippon Pharma to Sumitomo Pharma on April 1.
- 2019
Roivant subsidiaries are acquired
[1]Sumitomo Dainippon Pharma announces an approximately US$3 billion upfront transaction covering five Roivant subsidiaries.
- 2016
Cynapsus is acquired
[1]Sunovion announces the approximately US$624 million acquisition of Cynapsus Therapeutics and its Parkinson's disease candidate Kynmobi.
- 2010
Sepracor becomes Sunovion
[1]The acquired United States business is renamed Sunovion.
- 2009
Sepracor is acquired
[1]The company acquires United States-based Sepracor for approximately US$2.6 billion, establishing a stronger North American platform.
- 2005
Dainippon and Sumitomo Pharmaceuticals merge
[1]The two pharmaceutical lineages merge on October 1 to form Dainippon Sumitomo Pharma.
- 1984
Sumitomo Pharmaceuticals is incorporated
[1]Sumitomo Pharmaceuticals is established as a subsidiary of Sumitomo Chemical.
- 1898
Acquisition by Osaka Seiyaku
[1]After operating losses following Nagai Nagayoshi's departure, the early Dainippon business is acquired by Osaka Seiyaku.
- 1885
Dainippon Pharmaceuticals is established
[1]Nagayo Sensai establishes the predecessor business that later becomes part of Sumitomo Pharma.
Products and positioning
A research-oriented multinational pharmaceutical company using the Sumitomo corporate platform and international subsidiaries to develop and commercialize medicines for serious and underserved conditions, particularly in psychiatry, neurology, oncology, women's health, urology, rare diseases, and advanced therapies.
Psychiatry
Latuda
An atypical antipsychotic associated with Sunovion's North American commercial portfolio. It was approved for schizophrenia and for depressive episodes associated with bipolar I disorder and became one of the group's most commercially significant medicines.
Sleep medicine
Lunesta
A marketed medicine associated with the Sunovion portfolio. The available reference material identifies it as one of Sunovion's notable commercial products but does not provide additional product or launch details.
Neurology
Aptiom
A marketed medicine associated with Sunovion and the group's neurology portfolio. The supplied reference material does not specify further indications or launch timing.
Respiratory medicine
Brovana
A marketed product identified in the historical Sunovion portfolio. No additional product details are provided in the supplied reference material.
Parkinson's disease therapy
Kynmobi
A sublingual formulation of apomorphine obtained through Sunovion's acquisition of Cynapsus Therapeutics. It was developed for Parkinson's disease and was described in the acquisition material as a Phase III candidate at the time of the transaction.
Controversies
1940
Wartime production of Philopon methamphetamine
The historical Dainippon business produced methamphetamine under the Philopon brand for the Imperial Japanese military during the Second World War. The supplied reference identifies this as part of the company's wartime history but does not provide a more precise date or further legal details.
Brand decisions
2022
Rebrand as Sumitomo PharmaStrategyBackground
The company sought to operate under a unified corporate identity after its period as Sumitomo Dainippon Pharma.
Action taken
The corporate name was changed to Sumitomo Pharma on April 1, 2022.
Aftermath
The new name aligned the pharmaceutical company more directly with the Sumitomo identity.
2022
Acquire all outstanding Myovant sharesM&ABackground
Myovant was a former Roivant subsidiary in which Sumitomo Pharma had previously held a majority position.
Action taken
Sumitomo Pharma announced the acquisition of all outstanding Myovant shares at an announced valuation of approximately US$2.9 billion.
Aftermath
The transaction was completed in April 2023 and was followed by consolidation of the company's United States subsidiaries.
Announced valuation. Approximately US$2.9 billion (2022 announcement; completed April 2023)
2019
Acquire five Roivant subsidiariesM&ABackground
The company pursued broader exposure to specialty pharmaceutical opportunities.
Action taken
Sumitomo Dainippon Pharma announced an approximately US$3 billion upfront transaction for five Roivant subsidiaries, including Urovant and Enzyvant.
Aftermath
The transaction expanded the group's presence in urology, rare diseases, and related specialty areas.
Upfront transaction value. Approximately US$3 billion (2019)
2016
Acquire Cynapsus TherapeuticsM&ABackground
Sunovion sought to expand its central-nervous-system drug portfolio.
Action taken
Sunovion announced the acquisition of Cynapsus Therapeutics for approximately US$624 million.
Aftermath
The transaction added Kynmobi, a sublingual apomorphine product candidate for Parkinson's disease.
Acquisition value. Approximately US$624 million (2016)
2009
Acquire Sepracor to build a North American platformM&ABackground
Before the transaction, the company lacked a substantial sales foothold in North America.
Action taken
Sumitomo Dainippon Pharma acquired Sepracor for approximately US$2.6 billion and subsequently renamed the business Sunovion.
Aftermath
Sunovion provided a United States commercial platform and supported the marketing of Latuda, Lunesta, Aptiom, and Brovana.
Acquisition value. Approximately US$2.6 billion (2009)
Recent events
- 2025
Sumitomo Pharma share price declines after United States pharmaceutical tariff announcement[1]
Regulation · Pricing
On September 26, 2025, Sumitomo Pharma's stock price reportedly fell 5.33% after United States President Donald Trump announced new tariffs on pharmaceutical products.
- 2023
Sumitomo Pharma consolidates United States subsidiaries[1]
M&A
Following completion of the Myovant acquisition, Sumitomo Pharma consolidated its United States subsidiaries into Sumitomo Pharma America, Inc., a wholly owned biopharmaceutical subsidiary.
- 2022
Corporate name changed to Sumitomo Pharma[1]
Leadership change
The company changed its corporate name from Sumitomo Dainippon Pharma to Sumitomo Pharma on April 1, 2022.
- 2022
Sumitomo Pharma announces acquisition of Myovant[1]
M&A
Sumitomo Pharma announced an agreement to acquire all outstanding shares of Myovant, a former Roivant subsidiary in which it had previously held a majority position. The announced valuation was approximately US$2.9 billion.
- 2019
Sumitomo Dainippon Pharma announces acquisition of five Roivant subsidiaries[1]
M&A
The company announced an approximately US$3 billion upfront acquisition covering five Roivant subsidiaries, including Urovant and Enzyvant, broadening its specialty-pharmaceutical portfolio.
- 2016
Sunovion announces acquisition of Cynapsus Therapeutics[1]
M&A · Product launch
Sumitomo Dainippon Pharma's Sunovion subsidiary announced an approximately US$624 million acquisition of Cynapsus Therapeutics. The transaction was intended to strengthen the central-nervous-system portfolio and included Kynmobi, a sublingual apomorphine candidate for Parkinson's disease.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/sumitomo-pharma · Editorial policy · How profiles are compiled